Aurion Biotech, Inc. (“Aurion Biotech”), a commercial-stage regenerative cell therapy company dedicated to restoring vision and working toward a future where blindness is eliminated, today announced ...

SEATTLE & CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)--Aurion Biotech, Inc. (“Aurion Biotech”), a commercial-stage regenerative cell therapy company dedicated to restoring vision and working toward a ...

SEATTLE & CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)--Aurion Biotech, Inc. (Aurion Biotech), whose mission is to restore vision to millions of patients with life-changing regenerative therapies, today ...

Please provide your email address to receive an email when new articles are posted on . CHICAGO — In this Healio Video Perspective from Eyecelerator@AAO, Greg Kunst of Aurion Biotech provides an ...

Please provide your email address to receive an email when new articles are posted on . BOSTON — In this Healio Video Perspective from Eyecelerator@ASCRS, Greg Kunst, CEO of Aurion Biotech, discusses ...

Aurion Biotech, Inc. (“Aurion Biotech”), a commercial-stage regenerative cell therapy company dedicated to restoring vision, today announced that the company will present at the Eye Bank Association ...

This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye and improvements in restoring vision. In 1999, I defined ...

The highest dose of Aurion Biotech’s cell therapy, the main component of which recently received approval in Japan, has improved vision in a phase 1/2 trial for a type of eye disease, leading the ...

Aurion Biotech plans to list on the New York Stock Exchange under the symbol "AURN." (jxfzsy/iStock/Getty Images Plus) Cell therapy company Aurion Biotech is moving forward with plans to IPO despite a ...

SEATTLE & CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)-- Aurion Biotech, Inc. (Aurion), whose mission is to restore vision to millions of patients with life-changing regenerative therapies, announced ...

Aurion Biotech Doses First Patients in ASTRA Phase 3 Study, Evaluating AURN001 in Patients with Corneal Edema Secondary to Corneal Endothelial Dysfunction U.S. pivotal trial to assess efficacy and ...